Vimpat and Afinitor drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 264 people who take Vimpat and Afinitor. Common interactions include rash among females, and pyrexia among males.

The phase IV clinical study analyzes what interactions people who take Vimpat and Afinitor have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 28, 2023

264 people who take Vimpat and Afinitor together, and have interactions are studied.


What is Vimpat?

Vimpat has active ingredients of lacosamide. It is used in epilepsy. Currently, eHealthMe is studying from 19,605 Vimpat users.

What is Afinitor?

Afinitor has active ingredients of everolimus. It is used in breast cancer metastatic. Currently, eHealthMe is studying from 41,006 Afinitor users.

Number of Vimpat and Afinitor reports submitted per year:

Vimpat and Afinitor drug interactions.

Vimpat and Afinitor drug interactions by gender *:

Click here to view

Vimpat and Afinitor drug interactions by age *:

Click here to view

Common conditions people have *:

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take Vimpat and Afinitor?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Drug side effects by duration, gender and age:

Common Vimpat drug interactions:

Browse interactions between Vimpat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Afinitor drug interactions:

Browse interactions between Afinitor and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lacosamide and everolimus (the active ingredients of Vimpat and Afinitor, respectively), and Vimpat and Afinitor (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Vimpat and Afinitor.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: